metaMe Health Names Charlie Baum Chief Medical Officer

CHICAGO (June 11, 2018) -- Chicago-based metaMe Health has announced the appointment of Charlie Baum, MD, MS, FACG, as its Chief Medical Officer (CMO). metaMe provides Irritable Bowel Syndrome (IBS) sufferers with a clinically-proven therapy delivered through its flagship digital therapeutic for IBS Regulora™.

Charlie2.jpg

Dr. Baum is a board-certified Gastroenterologist and Physician Nutrition Specialist with more than 30 years of experience in healthcare. He has led clinical and basic science research in academia, and held executive positions in the pharmaceutical industry and more recently digital health sector. Dr. Baum is a graduate of the University of Chicago, where he also earned his medical degree and a master’s degree in nutrition.

“Through his leadership roles at Takeda Pharmaceuticals and Amita Health, Charlie has gained extensive experience in Regulatory Affairs, Reimbursement, and Physician Relations, three areas that will be critical to the success of metaMe,” said Danny Bernstein, CEO and Founder of metaMe Health. “We’re thrilled to have him on our team.”

Located in Chicago’s premier healthcare incubator MATTER, metaMe Health was created to help the more than 30 million Americans obtain much-needed relief from IBS. Instead of drugs, which treat only the gut symptoms, the company provides relief through a standardized Brain-Gut therapy approach that has been clinically proven to be effective in treating IBS. Patients access Regulora™ through the company’s HIPAA (health privacy)-compliant platform, metaMe Connect.

“The emergence of clinically-validated digital therapeutics as app-based treatments for medical conditions like IBS has made it an exciting time in healthcare,” said Dr. Baum. “metaMe is on the cutting-edge of this technology, and I Iook forward to becoming an integral part of the company’s success.”